Literature DB >> 17010131

Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder.

Nagisa Aoyama1, Nagahide Takahashi, Kiyoyuki Kitaichi, Ryoko Ishihara, Shinichi Saito, Nobuhisa Maeno, Xiaofei Ji, Kenji Takagi, Yoshimoto Sekine, Masaomi Iyo, Mutsuo Harano, Tokutaro Komiyama, Mitsuhiko Yamada, Ichiro Sora, Hiroshi Ujike, Nakao Iwata, Toshiya Inada, Norio Ozaki.   

Abstract

BACKGROUND: Methamphetamine (MAP) is one of the most frequently used illegal substances in Japan, and family and twin studies have suggested that genetic factors contribute to psychostimulant dependence, including MAP dependence. Organic cation transporter 3 (OCT3) has been reported to be involved in the disposition of MAP as well as MAP-induced behavioral changes in animals. Moreover, SLC22A3 (which encodes OCT3) is a candidate gene for MAP dependence because it is located within a chromosomal region associated with substance dependence.
METHODS: Using 96 healthy control subjects, linkage disequilibrium (LD) within the SLC22A3 was investigated, and 5 single-nucleotide polymorphisms (SNPs) were selected as haplotype tag SNPs to search for an association with MAP dependence. Single-marker analyses and haplotype analyses of these SNPs were performed in 213 subjects with MAP dependence and 443 healthy controls.
RESULTS: SLC22A3 polymorphisms were not significantly associated with MAP dependence in any of the single-marker and haplotype analyses. When subjects with MAP dependence were divided into polysubstance and single-MAP users, genotype and allele frequency of SNP2 (p=0.024, p=0.011, respectively), allele frequency of SNP3 (p=0.037), and haplotypic frequencies for these 2 SNPs (p=0.0438) differed significantly between groups.
CONCLUSIONS: These results suggest that polymorphisms of SLC22A3 are related to the development of polysubstance use in Japanese patients with MAP dependence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010131     DOI: 10.1111/j.1530-0277.2006.00215.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  21 in total

Review 1.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

2.  Differential genetic risk for methamphetamine intake confers differential sensitivity to the temperature-altering effects of other addictive drugs.

Authors:  John R K Mootz; Nicholas B Miner; Tamara J Phillips
Journal:  Genes Brain Behav       Date:  2020-01-15       Impact factor: 3.449

Review 3.  Genetic factors modulating the response to stimulant drugs in humans.

Authors:  Amy B Hart; Harriet de Wit; Abraham A Palmer
Journal:  Curr Top Behav Neurosci       Date:  2012

4.  Verification of a genetic locus for methamphetamine intake and the impact of morphine.

Authors:  Emily C Eastwood; Amy J Eshleman; Aaron Janowsky; Tamara J Phillips
Journal:  Mamm Genome       Date:  2017-11-10       Impact factor: 2.957

5.  Interaction of organic cation transporter 3 (SLC22A3) and amphetamine.

Authors:  Hao-Jie Zhu; David I Appel; Dirk Gründemann; John S Markowitz
Journal:  J Neurochem       Date:  2010-04-06       Impact factor: 5.372

Review 6.  Drug transporters in the human blood-placental barrier.

Authors:  Kirsi Vähäkangas; Päivi Myllynen
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

7.  Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice.

Authors:  Nicole L Baganz; Rebecca E Horton; Alfredo S Calderon; W Anthony Owens; Jaclyn L Munn; Lora T Watts; Nina Koldzic-Zivanovic; Nathaniel A Jeske; Wouter Koek; Glenn M Toney; Lynette C Daws
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

8.  The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway.

Authors:  Mei Cui; Radha Aras; Whitney V Christian; Phillip M Rappold; Mamata Hatwar; Joseph Panza; Vernice Jackson-Lewis; Jonathan A Javitch; Nazzareno Ballatori; Serge Przedborski; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-29       Impact factor: 11.205

Review 9.  Xenobiotic, bile acid, and cholesterol transporters: function and regulation.

Authors:  Curtis D Klaassen; Lauren M Aleksunes
Journal:  Pharmacol Rev       Date:  2010-01-26       Impact factor: 25.468

Review 10.  Genetics of methamphetamine use disorder: A systematic review and meta-analyses of gene association studies.

Authors:  Alexandre A Guerin; Eric J Nestler; Michael Berk; Andrew J Lawrence; Susan L Rossell; Jee Hyun Kim
Journal:  Neurosci Biobehav Rev       Date:  2020-11-17       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.